deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT00199849

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.

Sponsor: Ludwig Institute for Cancer Research

Conditions Bladder Cancer Esophageal Cancer Non-small Cell Lung Cancer Prostate Cancer Sarcoma
Interventions NY-ESO-1 Plasmid DNA Cancer Vaccine
Updated 8 times since 2017 Last updated: Oct 3, 2022 Started: Sep 27, 2004 Primary completion: Sep 11, 2006 Completion: Sep 30, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bladder Cancer and Esophageal Cancer, this trial is completed. The trial is conducted by Ludwig Institute for Cancer Research and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshotCompleted~Nov 2021 – ~Nov 2022 · 12 months · monthly snapshotCompleted~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Present [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1

  5. Nov 2021 — Nov 2022 [monthly]

    Completed PHASE1

▶ Show 3 earlier versions

  1. Jan 2021 — Nov 2021 [monthly]

    Completed PHASE1

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ludwig Institute for Cancer Research
  • M.D. Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • New York Presbyterian Hospital
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations